1
|
Zahid A, Wilson JC, Grice ID, Peak IR. Otitis media: recent advances in otitis media vaccine development and model systems. Front Microbiol 2024; 15:1345027. [PMID: 38328427 PMCID: PMC10847372 DOI: 10.3389/fmicb.2024.1345027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 01/08/2024] [Indexed: 02/09/2024] Open
Abstract
Otitis media is an inflammatory disorder of the middle ear caused by airways-associated bacterial or viral infections. It is one of the most common childhood infections as globally more than 80% of children are diagnosed with acute otitis media by 3 years of age and it is a common reason for doctor's visits, antibiotics prescriptions, and surgery among children. Otitis media is a multifactorial disease with various genetic, immunologic, infectious, and environmental factors predisposing children to develop ear infections. Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis are the most common culprits responsible for acute otitis media. Despite the massive global disease burden, the pathogenesis of otitis media is still unclear and requires extensive future research. Antibiotics are the preferred treatment to cure middle ear infections, however, the antimicrobial resistance rate of common middle ear pathogens has increased considerably over the years. At present, pneumococcal and influenza vaccines are administered as a preventive measure against otitis media, nevertheless, these vaccines are only beneficial in preventing carriage and/or disease caused by vaccine serotypes. Otitis media caused by non-vaccine serotype pneumococci, non-typeable H. influenza, and M. catarrhalis remain an important healthcare burden. The development of multi-species vaccines is an arduous process but is required to reduce the global burden of this disease. Many novel vaccines against S. pneumoniae, non-typeable H. influenza, and M. catarrhalis are in preclinical trials. It is anticipated that these vaccines will lower the disease burden and provide better protection against otitis media. To study disease pathology the rat, mouse, and chinchilla are commonly used to induce experimental acute otitis media to test new therapeutics, including antibiotics and vaccines. Each of these models has its advantages and disadvantages, yet there is still a need to develop an improved animal model providing a better correlated mechanistic understanding of human middle ear infections, thereby underpinning the development of more effective otitis media therapeutics. This review provides an updated summary of current vaccines against otitis media, various animal models of otitis media, their limitations, and some future insights in this field providing a springboard in the development of new animal models and novel vaccines for otitis media.
Collapse
Affiliation(s)
- Ayesha Zahid
- Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia
| | - Jennifer C. Wilson
- School of Pharmacy and Medical Science, Griffith University, Gold Coast, QLD, Australia
| | - I. Darren Grice
- Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia
- School of Pharmacy and Medical Science, Griffith University, Gold Coast, QLD, Australia
| | - Ian R. Peak
- Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia
- School of Pharmacy and Medical Science, Griffith University, Gold Coast, QLD, Australia
| |
Collapse
|
2
|
Zhou X, Gao M, De X, Sun T, Bai Z, Luo J, Wang F, Ge J. Bacterium-like particles derived from probiotics: progress, challenges and prospects. Front Immunol 2023; 14:1263586. [PMID: 37868963 PMCID: PMC10587609 DOI: 10.3389/fimmu.2023.1263586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 09/22/2023] [Indexed: 10/24/2023] Open
Abstract
Bacterium-like particles (BLPs) are hollow peptidoglycan particles obtained from food-grade Lactococcus lactis inactivated by hot acid. With the advantage of easy preparation, high safety, great stability, high loading capacity, and high mucosal delivery efficiency, BLPs can load and display proteins on the surface with the help of protein anchor (PA), making BLPs a proper delivery system. Owning to these features, BLPs are widely used in the development of adjuvants, vaccine carriers, virus/antigens purification, and enzyme immobilization. This review has attempted to gather a full understanding of the technical composition, characteristics, applications. The mechanism by which BLPs induces superior adaptive immune responses is also discussed. Besides, this review tracked the latest developments in the field of BLPs, including Lactobacillus-derived BLPs and novel anchors. Finally, the main limitations and proposed breakthrough points to further enhance the immunogenicity of BLPs vaccines were discussed, providing directions for future research. We hope that further developments in the field of antigen delivery of subunit vaccines or others will benefit from BLPs.
Collapse
Affiliation(s)
- Xinyao Zhou
- College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Mingchun Gao
- College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Xinqi De
- College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Tong Sun
- College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Zhikun Bai
- School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China
| | - Jilong Luo
- College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Fang Wang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin, China
| | - Junwei Ge
- College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
- Heilongjiang Provincial Key Laboratory of Zoonosis, Harbin, China
| |
Collapse
|
3
|
Li S, Liang H, Zhao SH, Yang XY, Guo Z. Recent progress in pneumococcal protein vaccines. Front Immunol 2023; 14:1278346. [PMID: 37818378 PMCID: PMC10560988 DOI: 10.3389/fimmu.2023.1278346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 09/07/2023] [Indexed: 10/12/2023] Open
Abstract
Pneumococcal infections continue to pose a significant global health concern, necessitating the development of effective vaccines. Despite the progress shown by pneumococcal polysaccharide and conjugate vaccines, their limited coverage and the emergence of non-vaccine serotypes have highlighted the need for alternative approaches. Protein-based pneumococcal vaccines, targeting conserved surface proteins of Streptococcus pneumoniae, have emerged as a promising strategy. In this review, we provide an overview of the advancements made in the development of pneumococcal protein vaccines. We discuss the key protein vaccine candidates, highlight their vaccination results in animal studies, and explore the challenges and future directions in protein-based pneumococcal vaccine.
Collapse
Affiliation(s)
- Sha Li
- Zhuhai Key Laboratory of Basic and Applied Research in Chinese Medicine, School of Bioengineering, Zunyi Medical University, Zhuhai, Guangdong, China
| | - Hangeri Liang
- Zhuhai Key Laboratory of Basic and Applied Research in Chinese Medicine, School of Bioengineering, Zunyi Medical University, Zhuhai, Guangdong, China
| | - Shui-Hao Zhao
- Center for Biological Science and Technology, Advanced Institute of Natural Sciences, Beijing Normal University, Zhuhai, Guangdong, China
| | - Xiao-Yan Yang
- Zhuhai Key Laboratory of Basic and Applied Research in Chinese Medicine, School of Bioengineering, Zunyi Medical University, Zhuhai, Guangdong, China
| | - Zhong Guo
- Center for Biological Science and Technology, Advanced Institute of Natural Sciences, Beijing Normal University, Zhuhai, Guangdong, China
| |
Collapse
|
4
|
Su K, Wang Y, Yuan C, Zhang Y, Li Y, Li T, Song Q. Intranasally inoculated bacterium-like particles displaying porcine epidemic diarrhea virus S1 protein induced intestinal mucosal immune response in mice. Front Immunol 2023; 14:1269409. [PMID: 37790942 PMCID: PMC10544335 DOI: 10.3389/fimmu.2023.1269409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2023] [Accepted: 08/31/2023] [Indexed: 10/05/2023] Open
Abstract
Porcine epidemic diarrhea virus (PEDV) causes acute watery diarrhea and high mortality in newborn piglets. Activation of intestinal mucosal immunity is crucial to anti-PEDV infection. To develop a vaccine capable of stimulating intestinal mucosal immunity, we prepared a bacterium (Lactococcus lactis)-like particle (BLP) vaccine (S1-BLPs) displaying the S1 protein, a domain of PEDV spike protein (S), based on gram-positive enhancer matrix (GEM) particle display technology. We further compared the effects of different vaccination routes on mucosal immune responses in mice induced by S1-BLPs. The specific IgG titer in serum of intramuscularly immunized mice with S1-BLPs was significantly higher than that of the intranasally administered. The specific IgA antibody was found in the serum and intestinal lavage fluid of mice vaccinated intranasally, but not intramuscularly. Moreover, the intranasally inoculated S1-BLPs induced higher levels of IFN-γ and IL-4 in serum than the intramuscularly inoculated. In addition, the ratio of serum IgG2a/IgG1 of mice inoculated intramuscularly was significantly higher with S1-BLPs compared to that of with S1 protein, suggesting that the immune responses induced by S1-BLPs was characterized by helper T (Th) cell type 1 immunity. The results indicated that S1-BLPs induced systemic and local immunity, and the immunization routes significantly affected the specific antibody classes and Th immune response types. The intranasally administered S1-BLPs could effectively stimulate intestinal mucosal specific secretory IgA response. S1-BLPs have the potential to be developed as PEDV mucosal vaccine.
Collapse
Affiliation(s)
- Kai Su
- College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- Hebei Veterinary Biotechnology Innovation Center, Baoding, Hebei, China
| | - Yawen Wang
- College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei, China
- Hebei Veterinary Biotechnology Innovation Center, Baoding, Hebei, China
| | - Chen Yuan
- College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- Hebei Veterinary Biotechnology Innovation Center, Baoding, Hebei, China
| | - Yanan Zhang
- College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei, China
- Hebei Veterinary Biotechnology Innovation Center, Baoding, Hebei, China
| | - Yanrui Li
- College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei, China
- Hebei Veterinary Biotechnology Innovation Center, Baoding, Hebei, China
| | - Tanqing Li
- College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei, China
- Hebei Veterinary Biotechnology Innovation Center, Baoding, Hebei, China
| | - Qinye Song
- College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei, China
- National Center of Technology Innovation for Pigs, Chongqing, China
- Hebei Veterinary Biotechnology Innovation Center, Baoding, Hebei, China
| |
Collapse
|
5
|
Mehanny M, Kroniger T, Koch M, Hoppstädter J, Becher D, Kiemer AK, Lehr C, Fuhrmann G. Yields and Immunomodulatory Effects of Pneumococcal Membrane Vesicles Differ with the Bacterial Growth Phase. Adv Healthc Mater 2022; 11:e2101151. [PMID: 34724354 DOI: 10.1002/adhm.202101151] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 10/22/2021] [Indexed: 12/20/2022]
Abstract
Streptococcus pneumoniae infections are a leading cause of death worldwide. Bacterial membrane vesicles (MVs) are promising vaccine candidates because of the antigenic components of their parent microorganisms. Pneumococcal MVs exhibit low toxicity towards several cell lines, but their clinical translation requires a high yield and strong immunogenic effects without compromising immune cell viability. MVs are isolated during either the stationary phase (24 h) or death phase (48 h), and their yields, immunogenicity and cytotoxicity in human primary macrophages and dendritic cells have been investigated. Death-phase vesicles showed higher yields than stationary-phase vesicles. Both vesicle types displayed acceptable compatibility with primary immune cells and several cell lines. Both vesicle types showed comparable uptake and enhanced release of the inflammatory cytokines, tumor necrosis factor and interleukin-6, from human primary immune cells. Proteomic analysis revealed similarities in vesicular immunogenic proteins such as pneumolysin, pneumococcal surface protein A, and IgA1 protease in both vesicle types, but stationary-phase MVs showed significantly lower autolysin levels than death-phase MVs. Although death-phase vesicles produced higher yields, they lacked superiority to stationary-phase vesicles as vaccine candidates owing to their similar antigenic protein cargo and comparable uptake into primary human immune cells.
Collapse
Affiliation(s)
- Mina Mehanny
- Helmholtz Institute for Pharmaceutical Research Saarland Biogenic Nanotherapeutics Group Campus E8.1 Saarbrücken 66123 Germany
- Department of Pharmacy Saarland University Campus E8.1 Saarbrücken 66123 Germany
- Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy Ain Shams University Cairo 11566 Egypt
| | - Tobias Kroniger
- Center for Functional Genomics of Microbes Department of Microbial Proteomics Institute of Microbiology University Greifswald Greifswald 17489 Germany
| | - Marcus Koch
- INM – Leibniz Institute for New Materials Campus D2.2 Saarbrücken 66123 Germany
| | - Jessica Hoppstädter
- Department of Pharmacy Pharmaceutical Biology Saarland University Saarbrücken 66123 Germany
| | - Dörte Becher
- Center for Functional Genomics of Microbes Department of Microbial Proteomics Institute of Microbiology University Greifswald Greifswald 17489 Germany
| | - Alexandra K. Kiemer
- Department of Pharmacy Pharmaceutical Biology Saarland University Saarbrücken 66123 Germany
| | - Claus‐Michael Lehr
- Department of Pharmacy Saarland University Campus E8.1 Saarbrücken 66123 Germany
- Helmholtz Institute for Pharmaceutical Research Saarland Drug Delivery Department Campus E8.1 Saarbrücken 66123 Germany
| | - Gregor Fuhrmann
- Helmholtz Institute for Pharmaceutical Research Saarland Biogenic Nanotherapeutics Group Campus E8.1 Saarbrücken 66123 Germany
- Department of Pharmacy Saarland University Campus E8.1 Saarbrücken 66123 Germany
- Friedrich‐Alexander‐University Erlangen‐Nürnberg Pharmaceutical Biology Department Biology Staudtstr. 5 Erlangen 91058 Germany
| |
Collapse
|
6
|
Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization. Vaccine 2021; 39:6920-6929. [PMID: 34696934 DOI: 10.1016/j.vaccine.2021.10.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 09/22/2021] [Accepted: 10/06/2021] [Indexed: 12/11/2022]
Abstract
Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a vaccine formulation. PBs can contain high concentrations of antigen, are stable and relatively resistant to proteases, release antigen slowly and are cost-effective to manufacture. Yet, the capacity of PBs to provoke immune responses and protection in the upper respiratory tract, a major entry route of respiratory pathogens, is largely unknown. In this study, we vaccinated mice intranasally with PBs comprising antigens from Streptococcus pneumoniae and evaluated the level of protection against nasopharyngeal colonization. PBs composed of the α-helical domain of pneumococcal surface protein A (PspAα) provided superior protection against colonization with S. pneumoniae compared to soluble PspAα. Immunization with soluble protein or PBs induced differences in antibody binding to pneumococci as well as a highly distinct antigen-specific nasal cytokine profile upon in vivo stimulation with inactivated S. pneumoniae. Moreover, immunization with PBs composed of conserved putative pneumococcal antigens reduced colonization by S. pneumoniae in mice, both as a single- and as a multi-antigen formulation. In conclusion, PBs represent a vaccine formulation that elicits strong mucosal immune responses and protection. The versatility of this platform offers opportunities for development of next-generation vaccine formulations.
Collapse
|
7
|
Walkowski W, Bassett J, Bhalla M, Pfeifer BA, Ghanem ENB. Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease. Vaccines (Basel) 2021; 9:vaccines9060589. [PMID: 34199398 PMCID: PMC8230341 DOI: 10.3390/vaccines9060589] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 05/17/2021] [Accepted: 05/22/2021] [Indexed: 12/17/2022] Open
Abstract
This mini-review will cover recent trends in intranasal (IN) vaccine delivery as it relates to applications for respiratory tract diseases. The logic and rationale for IN vaccine delivery will be compared to methods and applications accompanying this particular administration route. In addition, we will focus extended discussion on the potential role of IN vaccination in the context of respiratory tract diseases, with a special emphasis on pneumococcal disease. Here, elements of this disease, including its prevalence and impact upon the elderly population, will be viewed from the standpoint of improving health outcomes through vaccine design and delivery technology and how IN administration can play a role in such efforts.
Collapse
Affiliation(s)
- William Walkowski
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA; (W.W.); (J.B.); (B.A.P.)
| | - Justin Bassett
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA; (W.W.); (J.B.); (B.A.P.)
| | - Manmeet Bhalla
- Department of Microbiology and Immunology, University at Buffalo, The State University of New York, Buffalo, NY 14203, USA;
| | - Blaine A. Pfeifer
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA; (W.W.); (J.B.); (B.A.P.)
| | - Elsa N. Bou Ghanem
- Department of Microbiology and Immunology, University at Buffalo, The State University of New York, Buffalo, NY 14203, USA;
- Correspondence:
| |
Collapse
|
8
|
Rittenhouse-Olson K. Letter from the Editor 2020: Annual Summary and Introduction of the Thematic Issue and Guest Editor. Immunol Invest 2020; 49:687-691. [PMID: 33043771 DOI: 10.1080/08820139.2020.1810392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines (Basel) 2020; 8:vaccines8010132. [PMID: 32192117 PMCID: PMC7157650 DOI: 10.3390/vaccines8010132] [Citation(s) in RCA: 76] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 02/22/2020] [Accepted: 02/29/2020] [Indexed: 02/06/2023] Open
Abstract
Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S. pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover a wide range of serotypes. This review discusses the new approaches to develop effective vaccines with broad serotype coverage as well as recent development of promising pneumococcal vaccines in clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (Δpep27ΔcomD mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA). Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15 (V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed.
Collapse
|
10
|
Xu S, Jiao C, Jin H, Li W, Li E, Cao Z, Shi Z, Yan F, Zhang S, He H, Chi H, Feng N, Zhao Y, Gao Y, Yang S, Wang J, Wang H, Xia X. A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice. Viruses 2019; 11:v11121149. [PMID: 31835785 PMCID: PMC6950126 DOI: 10.3390/v11121149] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 12/01/2019] [Accepted: 12/07/2019] [Indexed: 01/24/2023] Open
Abstract
Sudan virus (SUDV) causes severe lethal hemorrhagic fever in humans and nonhuman primates. The most effective and economical way to protect against Sudan ebolavirus disease is prophylactic vaccination. However, there are no licensed vaccines to prevent SUDV infections. In this study, a bacterium-like particle (BLP)-based vaccine displaying the extracellular domain of the SUDV glycoprotein (eGP) was developed based on a gram-positive enhancer matrix-protein anchor (GEM-PA) surface display system. Expression of the recombinant GEM-displayed eGP (eGP-PA-GEM) was verified by Western blotting and immunofluorescence assays. The SUDV BLPs (SBLPs), which were mixed with Montanide ISA 201VG plus Poly (I:C) combined adjuvant, could induce high SUDV GP-specific IgG titers of up to 1:40,960 and robust virus-neutralizing antibody titers reached 1:460. The SBLP also elicited T-helper 1 (Th1) and T-helper 2 (Th2) cell-mediated immunity. These data indicate that the SBLP subunit vaccine has the potential to be developed into a promising candidate vaccine against SUDV infections.
Collapse
Affiliation(s)
- Shengnan Xu
- College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China; (S.X.); (Z.S.)
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
| | - Cuicui Jiao
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
| | - Hongli Jin
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Key Laboratory of Zoonosis Research, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun 130062, China
| | - Wujian Li
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Key Laboratory of Zoonosis Research, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun 130062, China
| | - Entao Li
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Zengguo Cao
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Key Laboratory of Zoonosis Research, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun 130062, China
| | - Zhikang Shi
- College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China; (S.X.); (Z.S.)
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
| | - Feihu Yan
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
| | - Shengnan Zhang
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- College of Wildlife and Protected Area, Northeast Forestry University, Harbin 150040, China
| | - Hongbin He
- Key Laboratory of Animal Resistant Biology of Shandong, Ruminant Diseases Research Center, College of Life Sciences, Shandong Normal University, Jinan 250014, China;
| | - Hang Chi
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225000, China
| | - Na Feng
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225000, China
| | - Yongkun Zhao
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225000, China
| | - Yuwei Gao
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225000, China
| | - Songtao Yang
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225000, China
| | - Jianzhong Wang
- College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China; (S.X.); (Z.S.)
- Correspondence: (J.W.); (X.X.)
| | - Hualei Wang
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Key Laboratory of Zoonosis Research, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun 130062, China
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225000, China
| | - Xianzhu Xia
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China; (C.J.); (H.J.); (W.L.); (E.L.); (Z.C.); (F.Y.); (S.Z.); (H.C.); (N.F.); (Y.Z.); (Y.G.); (S.Y.); (H.W.)
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225000, China
- Correspondence: (J.W.); (X.X.)
| |
Collapse
|